NCT02485106 is a Phase 3 clinical trial of Rifaximin in Severe Alcoholic Hepatitis, sponsored by Saint Vincent's Hospital, Korea.

Who is sponsoring NCT02485106?

NCT02485106 is sponsored by Saint Vincent's Hospital, Korea.

What drugs are being tested in NCT02485106?

Interventions in NCT02485106: Rifaximin, Corticosteroid or pentoxifylline.

What condition does NCT02485106 study?

NCT02485106 studies Severe Alcoholic Hepatitis.

Is NCT02485106 still recruiting?

NCT02485106 is currently status unknown. Last updated 25 June 2015.

Last reviewed 2015-06-25 · How we verify

NCT02485106

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis

Status unknown Phase 3 Last updated 25 June 2015

What this trial tests

Phase 3 trial testing Rifaximin in Severe Alcoholic Hepatitis in 170 participants. Status unknown.

Timeline

1 July 2015

Primary endpoint
1 December 2016

Quick facts

Lead sponsor	Saint Vincent's Hospital, Korea
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	170
Start date	1 July 2015
Primary completion	1 December 2016

Drugs / interventions tested

Rifaximin (rifaximin) — full drug profile →
Corticosteroid or pentoxifylline — full drug profile →

Conditions studied

Severe Alcoholic Hepatitis — all drugs for Severe Alcoholic Hepatitis →

Sponsor

Saint Vincent's Hospital, Korea

Who can join

Adults 19 to 75, any sex, with Severe Alcoholic Hepatitis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Mortality
Time frame: 6-month

Sponsor's own description

This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Promises of microbiome-based therapies.
Bajaj JS, Ng SC, Schnabl B. · · 2022 · cited 79× · PMID 35589257 · DOI 10.1016/j.jhep.2021.12.003
Management of decompensated cirrhosis.
Mansour D, McPherson S. · · 2018 · cited 74× · PMID 29700095 · DOI 10.7861/clinmedicine.18-2-s60
Gut-liver axis and sterile signals in the development of alcoholic liver disease.
Szabo G, Petrasek J. · · 2017 · cited 56× · PMID 28482064 · DOI 10.1093/alcalc/agx025
Treatment of Severe Alcoholic Hepatitis.
Thursz M, Morgan TR. · · 2016 · cited 53× · PMID 26948886 · DOI 10.1053/j.gastro.2016.02.074
Gut microbiota-modulating agents in alcoholic liver disease: Links between host metabolism and gut microbiota.
Jung JH, Kim SE, Suk KT, Kim DJ. · · 2022 · cited 23× · PMID 35935787 · DOI 10.3389/fmed.2022.913842
Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD, Kamel F, Kamel F, Tan J, et al · · 2023 · cited 22× · PMID 37467180 · DOI 10.1002/14651858.cd011585.pub2
Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives.
Ha Y, Jeong I, Kim TH. · · 2022 · cited 19× · PMID 36289791 · DOI 10.3390/biomedicines10102530
Emerging medical therapies for severe alcoholic hepatitis.
Tornai D, Szabo G. · · 2020 · cited 19× · PMID 32981291 · DOI 10.3350/cmh.2020.0145

Verify or expand the search:

Other trials of Rifaximin

Trials testing the same drug.

NCT07209371 — Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance · Phase 2 · recruiting
NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
NCT06483737 — Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) · NA · recruiting
NCT06808009 — Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Re · NA · not yet recruiting
NCT06652087 — Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction · NA · recruiting

Other Saint Vincent's Hospital, Korea trials

Trials by the same sponsor.

NCT07045623 — Comparison of Intensive Versus Standard Care & Education for Dyslipidemia in Hypertension and Diabetes Patients · NA · recruiting
NCT06756828 — Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer's Disease Spec · NA · not yet recruiting
NCT06477562 — Surveillance Endoscopy After Proximal Gastriectomy With Double Tract Reconstruction. · completed
NCT06186037 — Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy i · Phase 4 · recruiting
NCT05971225 — Verifying Remote Monitoring Effect on Net Cardiovascular Outcome; RemoteVerify (RêVe) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02485106 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Saint Vincent's Hospital, Korea
Last refreshed: 25 June 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02485106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing